Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
तुलना करने के लिए मीट्रिक्स | TRNG | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधTRNGपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −7.0x | −3.0x | −0.6x | |
PEG अनुपात | 0.28 | 0.04 | 0.00 | |
क़ीमत/बुक | −71.1x | 1.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 33.8x | 8.2x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | 97.6% | 126.9% | 41.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | 13.4% | 5.0% | अनलॉक करें |